Cantor Fitzgerald restated their buy rating on shares of Amarin Corporation PLC (NASDAQ:AMRN) in a research report sent to investors on Thursday. They currently have a $10.00 target price on the biopharmaceutical company’s stock.
Several other analysts also recently issued reports on the company. ValuEngine upgraded Amarin Corporation PLC from a sell rating to a hold rating in a report on Thursday, August 31st. BidaskClub downgraded Amarin Corporation PLC from a sell rating to a strong sell rating in a research note on Thursday, August 24th. HC Wainwright restated a buy rating and set a $10.00 target price on shares of Amarin Corporation PLC in a research note on Wednesday, August 9th. Zacks Investment Research downgraded Amarin Corporation PLC from a buy rating to a hold rating in a research note on Monday, August 7th. Finally, Jefferies Group LLC restated a buy rating and set a $7.00 target price on shares of Amarin Corporation PLC in a research note on Thursday, August 3rd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the stock. Amarin Corporation PLC has an average rating of Hold and a consensus price target of $7.35.
Amarin Corporation PLC (NASDAQ:AMRN) opened at 3.37 on Thursday. Amarin Corporation PLC has a 1-year low of $2.56 and a 1-year high of $4.47. The firm’s market capitalization is $912.57 million. The company’s 50-day moving average price is $3.28 and its 200 day moving average price is $3.31.
Amarin Corporation PLC (NASDAQ:AMRN) last announced its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.01. The company had revenue of $44.95 million during the quarter, compared to analyst estimates of $40.35 million. During the same quarter in the prior year, the company posted ($0.07) earnings per share. The firm’s revenue for the quarter was up 37.0% on a year-over-year basis. On average, equities analysts anticipate that Amarin Corporation PLC will post ($0.21) EPS for the current year.
ILLEGAL ACTIVITY WARNING: This news story was reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright law. The legal version of this news story can be read at https://www.chaffeybreeze.com/2017/09/17/cantor-fitzgerald-reaffirms-buy-rating-for-amarin-corporation-plc-amrn.html.
In other Amarin Corporation PLC news, General Counsel Joseph T. Kennedy sold 307,911 shares of the firm’s stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $4.00, for a total value of $1,231,644.00. The sale was disclosed in a legal filing with the SEC, which is available at this link. 3.72% of the stock is currently owned by company insiders.
Hedge funds and other institutional investors have recently modified their holdings of the business. Ameriprise Financial Inc. lifted its holdings in Amarin Corporation PLC by 0.9% in the first quarter. Ameriprise Financial Inc. now owns 395,769 shares of the biopharmaceutical company’s stock worth $1,266,000 after acquiring an additional 3,413 shares during the last quarter. Point72 Asset Management L.P. bought a new position in Amarin Corporation PLC in the first quarter worth about $960,000. Renaissance Technologies LLC lifted its holdings in Amarin Corporation PLC by 348.2% in the first quarter. Renaissance Technologies LLC now owns 1,730,200 shares of the biopharmaceutical company’s stock worth $5,537,000 after acquiring an additional 1,344,200 shares during the last quarter. Perkins Capital Management Inc. lifted its holdings in Amarin Corporation PLC by 20.3% in the second quarter. Perkins Capital Management Inc. now owns 41,500 shares of the biopharmaceutical company’s stock worth $167,000 after acquiring an additional 7,000 shares during the last quarter. Finally, Quantitative Investment Management LLC lifted its holdings in Amarin Corporation PLC by 105.1% in the first quarter. Quantitative Investment Management LLC now owns 187,900 shares of the biopharmaceutical company’s stock worth $601,000 after acquiring an additional 96,300 shares during the last quarter. 37.76% of the stock is currently owned by hedge funds and other institutional investors.
About Amarin Corporation PLC
Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.
Receive News & Ratings for Amarin Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin Corporation PLC and related companies with MarketBeat.com's FREE daily email newsletter.